Merck & Company, Inc. (MRK) Shares Bought by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 15.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 638,686 shares of the company’s stock after purchasing an additional 86,933 shares during the quarter. Merck & accounts for about 0.8% of Fjarde AP Fonden Fourth Swedish National Pension Fund’s investment portfolio, making the stock its 23rd biggest position. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Merck & were worth $40,933,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Perennial Advisors LLC increased its holdings in shares of Merck & by 10.7% during the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock worth $104,000 after purchasing an additional 157 shares during the period. Stelac Advisory Services LLC bought a new position in shares of Merck & during the 2nd quarter worth about $104,000. Vigilant Capital Management LLC increased its holdings in shares of Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after purchasing an additional 250 shares during the period. Cascade Investment Advisors Inc. increased its holdings in shares of Merck & by 15.5% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after purchasing an additional 232 shares during the period. Finally, Solaris Asset Management LLC increased its holdings in shares of Merck & by 6.3% during the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock worth $124,000 after purchasing an additional 115 shares during the period. Institutional investors own 73.15% of the company’s stock.

A number of analysts recently weighed in on the stock. raised shares of Merck & from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 9th. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Sanford C. Bernstein reissued a “buy” rating and issued a $64.00 target price on shares of Merck & in a research note on Wednesday. UBS AG upped their target price on shares of Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, July 31st. Finally, Barclays PLC cut shares of Merck & from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $72.00 to $62.00 in a research note on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $66.87.

Merck & Company, Inc. (NYSE MRK) opened at $55.20 on Friday. Merck & Company, Inc. has a 12-month low of $54.40 and a 12-month high of $66.80. The stock has a market cap of $150,388.92, a P/E ratio of 14.19, a PEG ratio of 2.38 and a beta of 0.78. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43.

Merck & (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The company had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. During the same period in the prior year, the business earned $1.07 earnings per share. Merck &’s quarterly revenue was down 2.0% on a year-over-year basis. research analysts anticipate that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Merck & Company, Inc. (MRK) Shares Bought by Fjarde AP Fonden Fourth Swedish National Pension Fund” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/19/merck-company-inc-mrk-shares-bought-by-fjarde-ap-fonden-fourth-swedish-national-pension-fund.html.

In other news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.25% of the stock is currently owned by corporate insiders.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply